Q32 BIO INC (QTTB)
US7469641051 - Common Stock
ChartMill assigns a Buy % Consensus number of 88% to QTTB. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 88.06. This target is 2788.25% above the current price.
QTTB was analyzed by 12 analysts. The buy percentage consensus is at 88. So analysts seem to be very confident about QTTB.
In the previous month the buy percentage consensus was at a similar level.
QTTB was analyzed by 12 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-12-12 | Guggenheim | Downgrade | Buy -> Neutral |
| 2024-12-12 | BMO Capital | Maintains | Outperform -> Outperform |
| 2024-12-11 | Leerink Partners | Downgrade | Outperform -> Market Perform |
| 2024-12-11 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2024-12-11 | Wells Fargo | Downgrade | Overweight -> Equal-Weight |
| 2024-12-11 | Raymond James | Downgrade | Strong Buy -> Outperform |
| 2024-12-11 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2024-12-06 | BMO Capital | Initiate | Outperform |
| 2024-10-24 | Raymond James | Initiate | Strong Buy |
| 2024-09-11 | Wells Fargo | Initiate | Overweight |
| 2024-06-17 | Guggenheim | Initiate | Buy |
| 2024-05-21 | Leerink Partners | Initiate | Outperform |
| 2024-04-11 | Oppenheimer | Initiate | Outperform |
| 2024-04-02 | Piper Sandler | Initiate | Overweight |